Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 28, 2014; 20(40): 14805-14820
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14805
Published online Oct 28, 2014. doi: 10.3748/wjg.v20.i40.14805
Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease
Zi-Kai Wang, Yun-Sheng Yang, Gang Sun, Li-Hua Peng, Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Chinese PLA Medical Academy, Beijing 100853, China
Ye Chen, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangdong Provincial Key Laboratory of Gastroenterology, Guangzhou 510515, Guangdong Province, China
Jing Yuan, Institute of Disease Control and Prevention, Academy of Military Medical Sciences, Beijing 100071, China
Author contributions: Wang ZK drafted this manuscript; Yang YS, Chen Y, Yuan J, Sun G and Peng LH edited and revised this manuscript; all authors have approved the final version of the manuscript.
Correspondence to: Yun-Sheng Yang, MD, PhD, Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Chinese PLA Medical Academy, 28 Fuxing Road, Beijing 100853, China. sunny301ddc@126.com
Telephone: +86-10-55499005 Fax: +86-10-55499005
Received: April 26, 2014
Revised: June 16, 2014
Accepted: July 16, 2014
Published online: October 28, 2014
Processing time: 185 Days and 21.3 Hours
Revised: June 16, 2014
Accepted: July 16, 2014
Published online: October 28, 2014
Processing time: 185 Days and 21.3 Hours
Core Tip
Core tip: Several lines of evidence strongly support the link between intestinal microbiota and inflammatory bowel disease (IBD). This review discusses the potential microbial pathogens, disturbance of intestinal microbiota, and immune interactions between host and microbes in IBD. Furthermore, alternative IBD treatment approaches aimed at restoring the disturbed intestinal microbiota have become a major interest in recent years. This article also reviews the present literature concerning the clinical use of probiotics, especially fecal microbiota transplantation and its barriers, and future directions in the management of IBD.